United Therapeutics (NASDAQ:UTHR) Given New $355.00 Price Target at JPMorgan Chase & Co.

United Therapeutics (NASDAQ:UTHR - Free Report) had its target price cut by JPMorgan Chase & Co. from $357.00 to $355.00 in a research report released on Monday,Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

Other equities analysts also recently issued research reports about the stock. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a research note on Monday. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $6.19 during mid-day trading on Monday, reaching $290.23. 52,717 shares of the company were exchanged, compared to its average volume of 446,514. The firm has a market cap of $13.03 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics has a 1 year low of $233.31 and a 1 year high of $417.82. The firm's 50-day simple moving average is $310.30 and its 200 day simple moving average is $346.99.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. During the same period last year, the business posted $4.36 EPS. On average, research analysts forecast that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $955,319.67. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 84,500 shares of company stock worth $28,179,150 over the last 90 days. Corporate insiders own 11.90% of the company's stock.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the business. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $25,000. Dunhill Financial LLC raised its stake in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in United Therapeutics during the 1st quarter valued at approximately $49,000. State of Wyoming acquired a new stake in United Therapeutics during the 4th quarter worth approximately $62,000. Finally, Millstone Evans Group LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.